Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

Erdheim-Chester disease - Google News
Rare disease fundraiser Aug. 29 at Gabby's Grill - Prescott Valley Tribune

Rare disease fundraiser Aug. 29 at Gabby's Grill
Prescott Valley Tribune
Gabby's Grill will host a fundraiser for Erdheim-Chester disease, an extremely rare disorder, from 4 to 8:30 p.m. on Tuesday, Aug. 29, at its location at 2982 N. Park Ave. #B, in Prescott Valley. The restaurant will give 25 percent of the bill for ...


Wednesday, August 23, 2017 9:06:40 AM

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation - Rare Disease Report

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
Rare Disease Report
The U.S. Food and Drug Administration (FDA) has accepted Genentech's supplemental New Drug Application (sNDA) and granted Priority Review for Zelboraf (vemurafenib), a therapy for patients with Erdheim-Chester disease (ECD) with a BRAF V600 ...
FDA grants priority review to Zelboraf for BRAF V600-mutated Erdheim-Chester disease
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester ...
FDA Grants Zelboraf Priority Review for Rare Blood Disease


Monday, August 07, 2017 10:29:49 AM

FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf in Erdheim-Chester Disease - National Pain Report

FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf in Erdheim-Chester Disease
National Pain Report
Here's good news for people with the rare blood disease, Erdheim-Chester disease (ECD): The U.S. Food and Drug Administration (FDA) accepted Genentech's supplemental New Drug Application (sNDA) and granted Priority Review for its drug, Zelboraf, for ...


Thursday, August 10, 2017 5:57:55 AM

FDA Grants Priority Review & Breakthrough Therapy Designation to Zelboraf - Drug Discovery & Development

Drug Discovery & Development

FDA Grants Priority Review & Breakthrough Therapy Designation to Zelboraf
Drug Discovery & Development
“We are committed to bringing new treatment options to people with rare diseases and hope to see Zelboraf approved for Erdheim-Chester disease as soon as possible.” A Priority Review designation is granted to medicines that the FDA has determined to ...


Wednesday, August 09, 2017 8:56:15 AM

FDA Grants Priority Review for Rare Blood Disease Drug - Specialty Pharmacy Times

FDA Grants Priority Review for Rare Blood Disease Drug
Specialty Pharmacy Times
The FDA on Monday granted Priority Review and Breakthrough Therapy Designation to vemurafenib (Zelboraf) for the treatment of Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib is designed to inhibit mutated forms of BRAF, and is ...
FDA gives Zelboraf priority review as potential first ever therapy for rare blood disease


Tuesday, August 08, 2017 11:42:34 AM

3 Things In Biotech You Should Learn Today: August 10, 2017 - Seeking Alpha

3 Things In Biotech You Should Learn Today: August 10, 2017
Seeking Alpha
But BRAF mutations can also be associated with nonmalignant conditions, such as the inflammatory disorder called Erdheim-Chester disease (ECD). This is where the body overproduces a certain kind of white blood cell called a histiocyte, which leads to ...


Thursday, August 10, 2017 9:00:25 AM

OncoBreak: Immunotherapy Resistance; Cancer and Opioids; Awkward Moment - MedPage Today

TIME

OncoBreak: Immunotherapy Resistance; Cancer and Opioids; Awkward Moment
MedPage Today
The FDA granted breakthrough therapy designation for the BRAF inhibitor vemurafenib (Zelboraf) for treatment of BRAF-mutant Erdheim-Chester disease, a rare condition affecting white blood cells. (Genentech). About all that excitement over immunotherapy ...
Sen. Johnson walks back remarks on McCain's brain cancer
Ron Johnson suggests McCain's brain cancer could have affected health care vote
Listen to EXCLUSIVE: Sen. John McCain in 1st interview says back to work in September | The Mike Broomhead Show ...
 -

Thursday, August 10, 2017 12:45:00 PM

Genes associated with Erdheim-Chester disease also linked to cancer - Science Daily

Genes associated with Erdheim-Chester disease also linked to cancer
Science Daily
National Human Genome Research Institute (NHGRI) researchers have identified new genes associated with the Erdheim-Chester disease (ECD) and some possible new therapies. Findings on this ultra-rare disease, found in approximately 600 people in the ...


Monday, April 03, 2017 12:40:33 PM

The ultra-rare Erdheim-Chester disease: Turning grief into a campaign for a cure - Washington Post

Washington Post

The ultra-rare Erdheim-Chester disease: Turning grief into a campaign for a cure
Washington Post
The cause was Erdheim-Chester disease (ECD), one of 7,000 diseases tracked by the nonprofit National Organization for Rare Disorders. The National Institutes of Health and the Food and Drug Administration call such ailments “orphan” diseases because ...


Monday, November 17, 2014 4:47:28 PM

NORD News for April - The Voice of the Community - Rare Disease Report

Rare Disease Report

NORD News for April - The Voice of the Community
Rare Disease Report
The Running for Rare Team made an outstanding showing at the 2017 Boston Marathon, with 14 runners and a large cheering section of NORD staff and rare disease Community Partners, who are patients, caregivers and patient advocates. The team runs ...


Monday, April 24, 2017 11:41:49 PM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us | Site Map
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!